Rapport Therapeutics, Inc. Common Stock (RAPP) - Stock Analysis
Last updated: Apr 4, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High liquidity ⢠Zero revenue ⢠Deep cash burn RAPP has a very strong balance sheet and low leverage supporting short-term solvency, but zero revenue, large operating losses and severe negative operating/free cash flow create acute profitability and cash-burn risks while the stock trades at a ~3x price-to-book premium.
Price Behavior
Key Price Behavior Insights: ⢠Short-term uptrend ⢠Range-top risk ⢠Breakout without volume Support Level: $27.00â$28.00 Resistance Level: $30.24â$31.29 Over the last month RAPP climbed ~13% from $29.65 to $33.58, clearing the intrarange high near $31.29 (buyer conviction) but trading at the range top with elevated volatility and no volume confirmation, so tighten stops or wait for a confirmed retest.
Sentiment & News
Key News Insights: ⢠Clinical efficacy ⢠China partnership ⢠Strong liquidity Rapport Therapeutics' RAPâ219 delivered strong Phase 2a results with Phase 3 planned in Q2 2026, secured a Greater China deal, reported a healthy cash runway, and saw growing investor interest.
AI Summary
RAPP has shifted from a binary discovery bet to a near-registrational, capital-light optionality storyâmaking on-time Phase 3 initiation/enrollment and milestone/licensing receipts the primary drivers of upside while trial delays, adverse data or slower partner payments are the key dilution/downside risks to monitor.
Description
Rapport Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system disorders. Its lead candidate, RAP-219, is a high-affinity inhibitor of TARPy8-containing AMPA receptors being evaluated for focal epilepsy and other CNS indications; the pipeline also includes an additional TARPy8 program and nicotinic acetylcholine receptor projects targeting chronic pain and hearing disorders. The company was incorporated in 2022, renamed from Precision Neuroscience NewCo in October 2022, and is based in Boston, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 15 | Sep 22 | RAPP | Rapport Therapeutics, Inc. Common Stock | Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term. | Closed | +5.6% |